58621-55-9

Basic information

• Product Name: 1-nitro-3-(prop-2-en-1-yloxy)benzene
• CAS NO: 58621-55-9
• Molecular Formula: C₉H₉NO₃
• Molecular Weight: 179.1727
• Mol File: 58621-55-9.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 295.7°C at 760 mmHg
• Flash Point: 138.9°C
• Density: 1.168g/cm³
• Vapor Pressure: 0.00265mmHg at 25°C
• Refractive Index: 1.544
• CAS DataBase Reference: 1-nitro-3-(prop-2-en-1-yloxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-nitro-3-(prop-2-en-1-yloxy)benzene(58621-55-9)
• EPA Substance Registry System: 1-nitro-3-(prop-2-en-1-yloxy)benzene(58621-55-9)

Safety Data

• Hazardous Substances Data: 58621-55-9(Hazardous Substances Data)

Usage

Appearance

Yellowish crystalline solid

Uses

Intermediate in the synthesis of pharmaceuticals and dyes

Reactivity

Highly reactive; can undergo nitration and reduction reactions

Toxicity

Can cause skin and eye irritation and other health hazards

Safety measures

Proper handling required in laboratory and industrial settings to avoid potential health risks

Upstream product

• 16278-29-8 3-nitrobenzenediazonium 
• 3118-78-3 potassium-3-nitrophenolate 
• 106-95-6 allyl bromide 
• 554-84-7 meta-nitrophenol 
• 107-18-6 allyl alcohol 

Downstream Products

• 5332-66-1 Glycidyl m-nitrophenyl ether 
• 58621-43-5 4-allyl-3-hydroxy-1-nitrobenzene 
• 58621-42-4 2-allyl-1-hydroxy-3-nitrobenzene 
• 1386383-63-6 trimethyl[4-(3-nitrophenoxy)but-2-enyl]silane 
• 1386383-66-9 trimethyl[4-(3-nitrophenoxy)but-2-enyl]silane 
• 1386383-62-5 4,4,5,5-tetramethyl-2-[4-(3-nitrophenoxy)but-2-enyl]-1,3,2-dioxaborolane 
• 1386383-64-7 4,4,5,5-tetramethyl-2-[4-(3-nitrophenoxy)but-2-enyl]-1,3,2-dioxaborolane 
• 1374646-36-2 (S,E)-1-(3-nitrophenoxy)hept-2-en-4-ol 
• 1374646-31-7 (R,E)-1-((tert-butyldimethylsilyl)oxy)-5-(3-nitrophenoxy)pent-3-en-2-ol 
• 1374646-39-5 (S,E)-1-cyclohexyl-5-(3-nitrophenoxy)pent-3-en-2-ol 
• 1374646-40-8 (S,E)-1-cyclohexyl-4-(3-nitrophenoxy)but-2-en-1-ol 
• 1374646-37-3 (S,e)-6-(3-nitrophenoxy)-1-phenylhex-4-en-3-ol 
• 1374646-34-0 (2S,3R,E)-1-((tert-butyldimethylsilyl)oxy)-2-methoxy-6-(3-nitrophenoxy)hex-4-en-3-ol 
• 1374646-35-1 (R,E)-1-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-(3-nitrophenoxy)but-2-en-1-ol 

Relevant articles and documents

Nickel-catalyzed deallylation of aryl allyl ethers with hydrosilanes

An efficient and mild catalytic deallylation method of aryl allyl ethers is developed, with commercially available Ni(COD)2 as catalyst precursor, simple substituted bipyridine as ligand and air-stable hydrosilanes. The process is compatible with a variety of functional groups and the desired phenol products can be obtained with excellent yields and selectivity. Besides, by detection or isolation of key intermediates, mechanism studies confirm that the deallylation undergoes η3-allylnickel intermediate pathway.

CHEMICAL COMPOUNDS

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormμLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be usefμL in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS

The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inh